Skip to content

EBITDA at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
Alkermes logo
AlkermesALKS
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
TG Therapeutics logo
TG TherapeuticsTGTX
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS

Other financials

Income statement

See full
Revenue--100%
Operating income-$105.9M-41.7%
Net income-$92.6M-33.6%
EPS (diluted)-$3.20+2.7%

Balance sheet

See full
Cash & equivalents$536.7M+223%
Total debt$1.4M+31.3%
Total equity$1.4B+221%
Total assets$1.5B+205%

Cash flow

See full
Operating cash flow-$86.2M-62.5%
CapEx$62.0K
Free cash flow-$86.2M-62.6%

Valuation

See full
Market cap$7.87B+1,075%
Enterprise value$7.34B+1,309%

Profitability

See full
Operating margin-3,927.5%-1,497pp
Net margin-3,658.5%-1,388pp
FCF margin-3,067.4%-1,030pp

Returns & leverage

See full
Return on equity-35.3%-10.9pp
Debt / equity0.0×
Current ratio15.9×+7.4×

Where this comes from

Calculated from Praxis Precision Medicines, Inc.’s reported figures.

$105.9Mebit+
$39.0KDepreciation Depletion & Amortization
=-$105.82M

The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Praxis Precision Medicines, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Praxis Precision Medicines, Inc.'s EBITDA?
Praxis Precision Medicines, Inc. (PRAX) reported EBITDA of -$105.82M in Q1 2026.
How has Praxis Precision Medicines, Inc.'s EBITDA changed year-over-year?
Praxis Precision Medicines, Inc.'s EBITDA decreased by 41.7% year-over-year, from -$74.68M to -$105.82M.
What is the long-term trend for Praxis Precision Medicines, Inc.'s EBITDA?
Over 4 years (2021 to 2025), Praxis Precision Medicines, Inc.'s EBITDA has grown at a 18.2% compound annual growth rate (CAGR), from -$167.15M to -$326.06M.
What does EBITDA mean?
Operating cash profit before interest, taxes, and non-cash charges.
How do you interpret EBITDA?
Higher is better and widely used to value capital-intensive businesses, but it ignores the real cost of capex — pair it with free cash flow. (Defined as EBIT + D&A so EBITDA = EBIT + D&A holds exactly.)
How does EBITDA compare across companies?
Standard cross-company operating-profit proxy for non-financials; not meaningful for banks and insurers.